Johnson & Johnson Acquires Pfizer Consumer Healthcare

On December 20, 2006, Johnson & Johnson Inc. announced the closing of its acquisition of Pfizer Consumer Healthcare for US$16.6 billion in cash. With the acquisition, the Johnson & Johnson Consumer Group portfolio will now feature products such as LISTERINE® oral care products, the NICORETTE® line of smoking cessation treatments, and SUDAFED® cold, flu and allergy products, in addition to Johnson & Johnson's own consumer and OTC products.

Johnson & Johnson was represented in Canada by Blake, Cassels & Graydon LLP, with a team consisting of Calvin S. Goldman, Q.C., Crystal Witterick, Jason Gudofsky and Micah Wood (competition), Andrea Freund (corporate), Iris Tam and Jacob Switzer (real property), Lee Shouldice and Caroline Helbronner (employment and benefits), Kathleen Penny (tax), Gary Daniel (intellectual property), and Allan Gelkopf and Robert Kreklewich (commodity tax).

Pfizer was represented in Canada by vice president legal affairs and general counsel Frank Monteleone and senior legal counsel Karyn Pellat-Caron, and by Cassels Brock & Blackwell LLP with a team led by Phil Spencer, Q.C. and that included Gary Steinhart, Stuart English and Jayne Westlake (corporate), Mark Nicholson, Carol Anne O'Brien and Yana Ermak (competition), Emily Larose (health), Jim Ayres (environmental), Bernice Karn (information technology), Tom Kapsales (real estate) and Andrew Reback (tax).